Massive Bio, a leader in AI-powered oncology patient recruitment and clinical trial matching, has been named in two pivotal categories on CB Insights’ latest AI Drug Research & Development Marke...
CHICAGO: Massive Bio, a leader in AI-powered oncology patient recruitment and clinical trial matching, has been named in two pivotal categories on CB Insights’ latest AI Drug Research & Development Market Map. This recognition underscores Massive Bio’s innovative contributions to revolutionizing cancer care through advanced artificial intelligence solutions.
CB Insights’ market map highlights companies at the forefront of leveraging AI to accelerate drug discovery and development. Massive Bio’s inclusion in both the “Clinical Trial Matching” and “Patient Recruitment” categories reflects its dual impact on streamlining clinical trial processes and enhancing patient access to cutting-edge therapies.
“Being recognized by CB Insights in two critical categories is a testament to our team’s dedication to transforming oncology care,” said Selin Kurnaz, PhD, CEO and Co-Founder of Massive Bio. “Our AI-driven platform is designed to bridge the gap between patients and clinical trials, ensuring that individuals receive the most appropriate and timely treatments available.”
Arturo Loaiza-Bonilla, MD, Co-Founder and Chief Medical Officer, added, “This acknowledgment validates our commitment to integrating advanced AI technologies into clinical workflows. By optimizing trial matching and patient recruitment, we’re not only improving operational efficiencies but also enhancing patient outcomes in oncology.”
This recognition from CB Insights follows a milestone presence at ASCO25, where Arturo Loaiza-Bonilla presented a poster session on AI-powered clinical trial matching and participated in the ASCO/ESMO Joint Session, emphasizing international collaboration in oncology innovation. In addition, Selin Kurnaz was named a PCC Wayfinder, honoring her leadership in advancing equitable access and data-driven transformation in cancer care.
Massive Bio’s platform utilizes sophisticated algorithms and real-time data analytics to match cancer patients with suitable clinical trials, considering factors such as genetic profiles, treatment histories, and geographic locations. This approach has significantly increased trial enrollment rates and reduced the time required to identify eligible participants.
The company’s dual recognition by CB Insights highlights its comprehensive approach to addressing challenges in clinical trial enrollment and patient engagement. As the demand for personalized cancer treatments grows, Massive Bio continues to lead in providing scalable, AI-driven solutions that connect patients with life-saving clinical trials.
About Massive Bio
Massive Bio, co-founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, it streamlines the patient journey, enhances access to advanced treatment options, and optimizes clinical trials. Massive Bio collaborates with pharmaceutical companies, research organizations, and healthcare institutions worldwide. A founding member of the CancerX public-private partnership and participant in the Cancer Moonshot White House initiative, the company has received recognition from the National Cancer Institute and operates across 17 countries with a global team of over 100 employees. For more information, visit www.massivebio.com.
Fonte: Business Wire
Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…
G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes
Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries
Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…
Today, Securonix, a five-time Leader in the Gartner® Magic Quadrant™ for Security Information and Event Management (SIEM), announced the acquisition of…
Anjuna, a leader in Confidential Computing and AI Data Fusion Clean Rooms, today announced the addition of a new top five global bank to its growing roster…
PubNub, the leader in real-time interactive apps, unveiled the next evolution of its platform. It introduces AI-native development, real-time decision…
Work AI leader Glean today announced it raised $150 million in Series F financing, bringing its valuation to $7.2 billion. The round was led by Wellington…